Cargando…
MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways
Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. However, its precise role in gastric cancer (GC) and the molecular mechanism of MeCP2 regulation are still largely unknown. Here we report that MeCP2 is highly express...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474507/ https://www.ncbi.nlm.nih.gov/pubmed/28131747 http://dx.doi.org/10.1016/j.ebiom.2017.01.021 |
_version_ | 1783244459617550336 |
---|---|
author | Zhao, Lingyu Liu, Yingxun Tong, Dongdong Qin, Yannan Yang, Juan Xue, Meng Du, Ning Liu, Liying Guo, Bo Hou, Ni Han, Jia Liu, Siyuan Liu, Na Zhao, Xiaoge Wang, Lumin Chen, Yanke Huang, Chen |
author_facet | Zhao, Lingyu Liu, Yingxun Tong, Dongdong Qin, Yannan Yang, Juan Xue, Meng Du, Ning Liu, Liying Guo, Bo Hou, Ni Han, Jia Liu, Siyuan Liu, Na Zhao, Xiaoge Wang, Lumin Chen, Yanke Huang, Chen |
author_sort | Zhao, Lingyu |
collection | PubMed |
description | Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. However, its precise role in gastric cancer (GC) and the molecular mechanism of MeCP2 regulation are still largely unknown. Here we report that MeCP2 is highly expressed in primary GC tissues and the expression level is correlated with the clinicopathologic features of GC. In our experiments, knockdown of MeCP2 inhibited tumor growth. Molecular mechanism of MeCP2 regulation was investigated using an integrated approach with combination of microarray analysis and chromatin immunoprecipitation sequencing (ChIP-Seq). The results suggest that MeCP2 binds to the methylated CpG islands of FOXF1 and MYOD1 promoters and inhibits their expression at the transcription level. Furthermore, we show that MeCP2 promotes GC cell proliferation via FOXF1-mediated Wnt5a/β-Catenin signaling pathway and suppresses apoptosis through MYOD1-mediated Caspase-3 signaling pathway. Due to its high expression level in GC and its critical function in driving GC progression, MeCP2 represents a promising therapeutic target for GC treatment. |
format | Online Article Text |
id | pubmed-5474507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-54745072017-06-26 MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways Zhao, Lingyu Liu, Yingxun Tong, Dongdong Qin, Yannan Yang, Juan Xue, Meng Du, Ning Liu, Liying Guo, Bo Hou, Ni Han, Jia Liu, Siyuan Liu, Na Zhao, Xiaoge Wang, Lumin Chen, Yanke Huang, Chen EBioMedicine Research Paper Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. However, its precise role in gastric cancer (GC) and the molecular mechanism of MeCP2 regulation are still largely unknown. Here we report that MeCP2 is highly expressed in primary GC tissues and the expression level is correlated with the clinicopathologic features of GC. In our experiments, knockdown of MeCP2 inhibited tumor growth. Molecular mechanism of MeCP2 regulation was investigated using an integrated approach with combination of microarray analysis and chromatin immunoprecipitation sequencing (ChIP-Seq). The results suggest that MeCP2 binds to the methylated CpG islands of FOXF1 and MYOD1 promoters and inhibits their expression at the transcription level. Furthermore, we show that MeCP2 promotes GC cell proliferation via FOXF1-mediated Wnt5a/β-Catenin signaling pathway and suppresses apoptosis through MYOD1-mediated Caspase-3 signaling pathway. Due to its high expression level in GC and its critical function in driving GC progression, MeCP2 represents a promising therapeutic target for GC treatment. Elsevier 2017-01-17 /pmc/articles/PMC5474507/ /pubmed/28131747 http://dx.doi.org/10.1016/j.ebiom.2017.01.021 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Zhao, Lingyu Liu, Yingxun Tong, Dongdong Qin, Yannan Yang, Juan Xue, Meng Du, Ning Liu, Liying Guo, Bo Hou, Ni Han, Jia Liu, Siyuan Liu, Na Zhao, Xiaoge Wang, Lumin Chen, Yanke Huang, Chen MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title | MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title_full | MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title_fullStr | MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title_full_unstemmed | MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title_short | MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways |
title_sort | mecp2 promotes gastric cancer progression through regulating foxf1/wnt5a/β-catenin and myod1/caspase-3 signaling pathways |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474507/ https://www.ncbi.nlm.nih.gov/pubmed/28131747 http://dx.doi.org/10.1016/j.ebiom.2017.01.021 |
work_keys_str_mv | AT zhaolingyu mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT liuyingxun mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT tongdongdong mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT qinyannan mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT yangjuan mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT xuemeng mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT duning mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT liuliying mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT guobo mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT houni mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT hanjia mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT liusiyuan mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT liuna mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT zhaoxiaoge mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT wanglumin mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT chenyanke mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways AT huangchen mecp2promotesgastriccancerprogressionthroughregulatingfoxf1wnt5abcateninandmyod1caspase3signalingpathways |